ClinicaliQ Trial Snapshot
- Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — Recruiting • Phase II • NCT07224360.
- Early-stage trial testing whether a new injection drug is safe and well-tolerated in adults with sickle cell disease over 64 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period. Conditions: Sickle Cell Disease Interventions: Anumigilimab,…